Baseline characteristics of patients.

<p>Baseline characteristics of patients.</p

HbA1c after DPP-4I in patients with no drug discontinuation.

<p>HbA1c after DPP-4I in patients with no drug discontinuation.</p

HbA1c after DPP4-I in patients with no prior prescription, discontinuation or dosage change of ADA other than DPP-4I.

<p>HbA1c after DPP4-I in patients with no prior prescription, discontinuation or dosage change of ADA other than DPP-4I.</p

Change in HbA1c after DPP4-I treatment according to <i>CDKAL1</i> genotypes.

<p>SNP rs7754840 (left) and rs7756992 (right). Each line shows a change in HbA1c from baseline.* P < 0.025 and **P < 0.001 for comparisons between genotypes.</p

Multivariate analysis of HbA1c after DPP-4I.

<p>Multivariate analysis of HbA1c after DPP-4I.</p

HbA1c after DPP-4I monotherapy or combination therapy.

<p>HbA1c after DPP-4I monotherapy or combination therapy.</p

By-Laws of the Cooperative

Additional file 3.  Routine blood and urine examination

MOESM1 of Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study

Additional file 1. Trial organization

MOESM1 of Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial

Additional file 1. Blood examination

MOESM2 of Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial

Additional file 2. AESI definitions